High-frequency spinal cord stimulation provides better results in chronic back and leg pain
October 28, 2016 – For patients with severe, chronic back and leg pain, a new high-frequency spinal cord stimulation (SCS) technique provides superior clinical outcomes, compared to conventional low-frequency SCS, reports a clinical trial in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Wolters Kluwer.
The new 'HF10' technique offers lasting reductions in back and leg pain after other treatments have failed, according to the report by Dr. Leonardo Kapural of the Center for Clinical Research and Carolinas Pain Institute, Winston-Salem, N.C., and colleagues. They believe that HF10 therapy could have a major impact on the treatment of chronic back and leg pain, and possibly other conditions as well.
With HF10, Lasting Reduction in Pain Scores at Two Years' Follow-up
The study included 171 patients with moderate to severe back and leg pain that persisted despite other treatments. Treated at 11 US comprehensive pain centers, the patients had chronic pain that had been present for an average of 14 years. Nearly 90 percent had had previous back surgery; a similar proportion were taking opioid pain medications.
After a trial period, patients were randomly assigned to one of two SCS techniques, with mild electrical stimulation applied to targeted spinal nerves. One group was treated using HF10, with high-frequency stimulation (10 kilohertz) applied for very short periods. The other group received traditional SCS, with lower-frequency stimulation applied for relatively longer periods.
As previously reported, HF10 provided superior pain relief. At three months, scores for back and leg pain decreased by at least half in more than 80 percent of patients receiving HF10. By comparison, conventional SCS achieved similar responses in back pain for 44 percent of patients and in leg pain for 55 percent.
At two years' follow-up, the HF10 group still had higher response rates: 76 versus 49 percent for back pain and 73 versus 49 percent for leg pain. On a 0-to-10 rating scale, average back pain score decreased by 5 points with HF10 versus about 3 points for traditional SCS. About 60 percent of patients receiving HF10 were "very satisfied" with their treatment, compared to 40 percent with conventional SCS.
Although SCS is not a new treatment, it provides more consistent results for leg pain than back pain, and relies on producing overlapping areas of numbness (paresthesia) to mask pain. By comparison, HF10 seems to provide greater relief of back pain without inducing areas of numbness. The new study is among the few to directly compare different approaches to SCS in patients with back and leg pain.
Within its limitations, the pragmatic clinical trial supports the superiority of HF10 over conventional SCS for patients with chronic, severe back and leg pain. Extending follow-up to two years "provides physicians, patients, and payers with rigorous evidence demonstrating the durability of SCS in treating chronic pain," Dr. Kapural and coauthors write. They note that the results are "particularly impressive" given the patients' long history of pain and lack of response to other treatments, including back surgery.
Further research will determine whether HF-10 is useful for other chronic pain problems as well, such as arm and neck pain. Dr. Kapural and colleagues conclude: "The superior and durable results demonstrated in this study are anticipated to lead to improved long-term cost effectiveness and payer acceptance, making this therapy broadly available to patients suffering from chronic pain."
Click here to read "Comparison of 10-kHz High-Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial."
Article: "Comparison of 10-kHz High-Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial" (doi: 10.1227/NEU.0000000000001418)
Neurosurgery, the Official Journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit http://www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.